Se connecter

Bibliographies thématiques / Arformoterol

Sommaire

Articles de revues
Chapitres de livres
Actes de conférences

Littérature scientifique sur le sujet « Arformoterol »

Auteur : Grafiati

Publié le 7 juin 2025

Mis à jour le 2 août 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Arformoterol ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Arformoterol"

1

King, Paul T. "Pharmacotherapy of Chronic Obstructive Pulmonary Disease: Focus on Arformoterol Tartrate." Clinical Medicine. Therapeutics 1 (January 2009): CMT.S2584. http://dx.doi.org/10.4137/cmt.s2584.

Texte intégral

Résumé :

Arformoterol tartrate is a newly developed long-acting ssβ2-agonist with both acute and prolonged bronchodilator effects. It is formed of 2 isomers (R,R/R,R) which distinguishes it from the more commonly used racemic formoterol (R,R/S,S). The active isomer is the (R,R) and in vitro arformoterol may have more potent anti-inflammatory effects than formoterol. It can only be given by a nebulizer. There have been 5 randomized, blinded trials which have assessed the use of arformoterol in chronic obstructive pulmonary disease (COPD). Arformoterol has been demonstrated to improve lung function and s

Styles APA, Harvard, Vancouver, ISO, etc.

2

&NA;. "Arformoterol." Drugs in R & D 5, no. 1 (2004): 25–27. http://dx.doi.org/10.2165/00126839-200405010-00004.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Hazra, Moumita. "A pharmacoepidemiological study of prescription patterns of β2 sympathomimetic bronchodilators in exacerbation of non-severe asthma in tertiary care hospitals, not needing hospitalization". International Journal of Basic & Clinical Pharmacology 8, № 12 (2019): 2674. http://dx.doi.org/10.18203/2319-2003.ijbcp20195276.

Texte intégral

Résumé :

Background: Arformoterol, the (R, R) enantiomer of the racemic (R, R / S, S) diastereomer, formoterol, is a short and long acting β2 agonist bronchodilator. Levosalbutamol, the (R, R) enantiomer of racemic diastereomer (R, R / S, S) salbutamol, has a greater affinity for the β2 receptor. Occupation of β2 receptors by agonists result in the activation of the Gs-adenylyl cyclase-cAMP-PKA pathway, followed by phosphorylative events leading to bronchial smooth muscle relaxation. The aim of this pharmacoepidemiological study was to analyse the prescription patterns, and prescription content analysi

Styles APA, Harvard, Vancouver, ISO, etc.

4

Cada, Dennis J., Terri Levien, and Danial E. Baker. "Arformoterol Tartrate." Hospital Pharmacy 42, no. 5 (2007): 447–54. http://dx.doi.org/10.1310/hpj4205-447.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Revill, P., N. Serradell, J. Bolós, and M. Bayés. "Arformoterol Tartrate." Drugs of the Future 31, no. 11 (2006): 944. http://dx.doi.org/10.1358/dof.2006.031.11.1047743.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

&NA;. "Arformoterol comparable to salmeterol for COPD." Inpharma Weekly &NA;, no. 1558 (2006): 6. http://dx.doi.org/10.2165/00128413-200615580-00013.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Cazzola, Mario, Nicola A. Hanania, and Maria G. Matera. "Arformoterol tartrate in the treatment of COPD." Expert Review of Respiratory Medicine 4, no. 2 (2010): 155–62. http://dx.doi.org/10.1586/ers.10.16.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Bhutnar, Arun, Anita Desai, Sachin Khapare, Sonali Vartak, Ajay Pangavhane, and Allwyn Andrandes. "Identification and Structural Characterization of Secondary Degradant of Arformoterol Impurity in LDPE Respules of Arformoterol Tartrate Inhalation Solution." American Journal of Analytical Chemistry 09, no. 05 (2018): 286–301. http://dx.doi.org/10.4236/ajac.2018.95022.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

King, Paul. "Role of arformoterol in the management of COPD." International Journal of Chronic Obstructive Pulmonary Disease Volume 3 (September 2008): 385–91. http://dx.doi.org/10.2147/copd.s753.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Jeong, Jin-Hyuk, Jaewoon Son, Ji-Hyeon Kwon, Chang-Soo Han, and Chun-Woong Park. "Impact of Different Hydrate Forms of Magnesium Stearate as a Flow Control Agent on the Physical Stability and Inhalation Efficiency of Carrier-Based Formulations." Pharmaceutics 17, no. 6 (2025): 711. https://doi.org/10.3390/pharmaceutics17060711.

Texte intégral

Résumé :

Objectives: This study aimed to evaluate the impact of the different hydration states of magnesium stearate (Mg.st) anhydrate (AH), monohydrate (MH), and dihydrate (DH) on the aerodynamic performance and stability of carrier-based dry powder inhalation (DPI) formulations using arformoterol and budesonide as model drugs. Methods: DPI formulations were prepared using Inhalac 251 lactose and Mg.st in various hydrated forms. The physicochemical properties of Mg.st were characterized using powder X-ray diffraction, differential scanning calorimetry, Fourier-transform infrared spectroscopy, Karl Fis

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Chapitres de livres sur le sujet "Arformoterol"

1

"ARFORMOTEROL." In Litt's Drug Eruptions & Reactions Manual. CRC Press, 2010. http://dx.doi.org/10.3109/9781841847665-19.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

"Arformoterol." In Hale’s Medications & Mothers’ Milk™ 2019. Springer Publishing Company, 2018. http://dx.doi.org/10.1891/9780826150356.0063.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Arformoterol"

1

Panettieri, R., J. Walsh, M. Sims та ін. "Comparison of Efficacy and Safety of Arformoterol 15 μg Twice Daily with Arformoterol 30 μg Once Daily in Patients with COPD." У American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4542.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Karafilidis, John, Noelle Wilson, and Kenneth Sciarappa. "Evaluation Of Efficacy Following Arformoterol Tartrate 15 µg And Formoterol Fumarate 12 µg In Patients With Moderate To Severe COPD Stratified By Baseline Inspiratory Capacity." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a2934.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Sciarappa, Kenneth, and John Karafilidis. "An Evaluation Of Response Rates Following Treatment With Nebulized Arformoterol 15 µg, Salmeterol MDI 42 µg Or Placebo Twice Daily In Patients With Moderate COPD." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1588.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Karafilidis, John. "By Age Evaluation Of Efficacy And Safety Following Treatment With Nebulized Arformoterol 15 G, Salmeterol 42 G MDI And Placebo Twice Daily In Patients With Moderate COPD." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1587.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Bauer, Andrea, Jay Holt, Eric Stewart, et al. "In Vitro Analysis Of The Effect Of Air Flow Rate On The Aerosol Properties Of Nebulized Arformoterol And Tiotropium And Fluticasone/Salmeterol Delivered Via Dry Powder Inhalers." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1601.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!